Asymptomatic MGD more common than symptomatic

Article

A symptom-based approach may lead to an underestimation of MGD prevalence

"The high proportion of asymptomatic patients should alert us to the possibility of unnoticed progression of meibomian gland dysfunction (MGD)," emphasized Dr Eloy Viso (Servico de Oftalmología, Complexo Hospitalario de Pontevedra, Pontevedra, Spain) when discussing the results of a recent study on a general Spanish adult population.

The study

A population-based approach was used to obtain a representative sample of the population noted Dr Viso. The possibility of selection bias was also evaluated to ensure the results were fair. "We used a stratified sampling procedure so a representative sample could be obtained in each age group and we performed a design based analysis to account for the stratified sampling and the unequal probability selection," added Dr Viso. "With respect to diagnostic criteria, which are an important cause of variability between studies, we included signs of the 2 categories described in the new MGD classification to reduce the number of false negatives and removed indirect indicators to reduce the number of false positives."

Additionally, a standardized symptoms questionnaire was employed. "We used the questionnaire developed by Schein et al.1 because it was the most widely used in population-based studies and because it included symptoms such as eyes stuck shut that have been considered, in spite of a lack of sufficient evidence, more characteristic of MGD," he continued. "The biomicroscopic examination of the ocular surface, however, was performed without knowledge of the results of the questionnaire."

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Related Content
© 2025 MJH Life Sciences

All rights reserved.